Bydureon BCise
strong$720-$880/mo cash price
Same molecule (exenatide) reformulated for once-weekly extended release via the ABLE microsphere autoinjector.
Better adherence than twice-daily Byetta dosing.
View Bydureon BCise on GLP1ZoomAffiliate-supportedIndependent editorialWe never sell medicationSee how
Alternatives
A printable summary of therapeutic alternatives to Byetta (exenatide), the current FDA generic-status outlook, and the questions to bring to your prescriber visit.
Active ingredient
exenatide
FDA generic status
Not yet approved
Patent / NDA holder
AstraZeneca (originally Amylin / Lilly)
Estimated generic year
~2027 (patents largely expired; pen-device patents remain)
Exenatide composition-of-matter patents have expired but proprietary pen-injector and ABLE drying-microsphere patents (for Bydureon BCise) remain. No FDA-approved generic exenatide pen had launched in the US as of 2026. The Byetta brand was discontinued in 2024.
Equivalence strength reflects shared mechanism of action plus the depth of head-to-head clinical evidence. Costs are US cash-price estimates and vary widely by pharmacy, insurance, and manufacturer copay programs.
$935-$1,000/mo cash price
Newer-generation once-weekly GLP-1 with stronger glycemic + weight outcomes than exenatide.
Most exenatide patients transition to semaglutide or tirzepatide when accessible.
View Ozempic on GLP1Zoom$945-$985/mo cash price
Once-weekly dulaglutide with auto-injector and CV-outcome data.
Single-use device simplifies adherence.
View Trulicity on GLP1Zoom$4-$25/mo cash price
First-line oral diabetes therapy.
Low-cost baseline therapy.
$0-$250/mo cash price
No medication side-effect risk. Average weight loss with intensive lifestyle programs is 5-10% of body weight over 12 months — meaningful for some patients, well below GLP-1 efficacy for others.
Often combined with — not replacing — GLP-1 therapy; insurance may cover RD visits under obesity-care benefits.
Bring this summary to a visit, or connect with a telehealth GLP-1 prescriber who can review your insurance, dosing history, and tolerability before recommending any switch.
Partner offers first — we earn a commission from those — then ranked by our editorial score. Visit a partner to check current pricing and eligibility — we compare providers, we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money